The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Full approval will depend on verification of clinical benefit in a confirmatory trial
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
GV20 received an upfront payment and is eligible for additional milestone payments
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Subscribe To Our Newsletter & Stay Updated
